Cost-effective, innovative approaches are needed to accelerate progress towards ending preventable infant, child and maternal mortality. To inform policy decisions, we conducted a costeffectiveness analysis of adding urine pregnancy test kits to the maternal and reproductive services package offered at the community level in Madagascar, Ethiopia and Malawi. We used a decision tree model to compare the intervention with the status quo for each country. We also completed single factor sensitivity analyses and Monte Carlo simulations with 10 000 iterations to generate the probability distribution of the estimates and uncertainty limits. Among a hypothetical cohort of 100 000 women of reproductive age, we estimate that over a 1-year period, the intervention would Based on WHO criteria and a comparison with other maternal, newborn, and child health interventions, we conclude that the addition of urine pregnancy tests to an existing community health worker maternal and reproductive services package is highly cost-effective in all three countries. To optimize uptake of family planning and antenatal care services and, in turn, accelerate the reduction of mortality and DALYs, decision makers and program planners should consider adding urine pregnancy tests to the community-level package of services.
Introduction
Over the past two decades, many developing countries have made major progress in reducing mortality among children under-5 years of age. However, maternal and infant mortality rates remain high. High-impact, cost-effective health services delivered at the community level can increase access to life-saving interventions. We developed a decision tree model to estimate the costs and potential mortality reductions that could result from scaling-up the use of urine pregnancy test kits distributed at the community level. The model was specified for Madagascar, Ethiopia and Malawi: three countries with large community health worker (CHW) programs that provide family planning and maternal health services. The purpose of this study is to inform policy decisions on the inclusion of pregnancy test kits as part of the community-based maternal and reproductive services package in order to accelerate progress towards the global priority of ending preventable infant and maternal mortality.
Context
The United Nations Sustainable Development Goals set ambitious new health development targets to be achieved by 2030. These targets include ensuring universal access to sexual and reproductive health care services, including family planning; reducing global maternal mortality and, ending preventable deaths of newborns and children. The achievement of these ambitious targets will require the use of cost-effective technical innovations (Sustainable Development Goals 2016).
A review of the evidence

Family planning
Pregnancy and delivery entail a risk of death and this risk is significantly higher in sub-Saharan Africa where there are an estimated 500 maternal deaths out of 100 000 live births, as compared to 11 maternal deaths in developed regions (WHO 2015) . It is estimated that use of family planning in countries with high birth rates could avert 32% of maternal deaths and up to 10% of childhood deaths (Cleland et al. 2006) . There are several mechanisms through which adoption of family planning could reduce maternal mortality: first, through primary prevention by avoiding pregnancy for women who do not wish to become pregnant; and, second, through risk reduction by delaying childbirth and increasing birth spacing, since higher parity and births, particularly among very young or older women, have a higher risk of maternal death (Campbell and Graham 2006) . While there is mixed evidence on the mortality impact for the mother from greater birth spacing, there is stronger evidence of the benefits of birth spacing for reducing infant and child mortality (Ronsmans and Campbell 1998 ; Conde-Agudelo and Beliz an 2000; Cleland et al. 2006] . Adoption of effective family planning would reduce unwanted pregnancies which account for 40% of pregnancies globally, of which 50% result in induced abortion (Sedgh et al. 2014) . It is estimated that preventing unplanned and unwanted pregnancies could reduce maternal mortality by 25-40% (Campbell and Graham 2006) .
Antenatal care
In 2015, approximately 45% of global under-five deaths occurred during the first month of life (World Health Organization 2016) . The antenatal care (ANC) service package, recommended as four or more health center visits during the prenatal period, is estimated to reduce all-cause neonatal mortality worldwide by 10-20% (Darmstadt et al. 2005) . The early initiation of ANC is highly desirable as it increases the odds that a woman will complete four or more ANC visits to receive the full service package, thus maximizing the reduction in neonatal mortality.
Early identification and prevention of underlying conditions (such as malaria complications, congenital syphilis, and anemia) are critical for the effective delivery of ANC. Thus, ANC should begin as early as possible and optimally in the first trimester (Antenatal Care 2005; Kuznik et al. 2013) . In sub-Saharan Africa, women presenting for ANC are more likely to wait until the second trimester and a substantial proportion present only in the third trimester (Abou-Zahr and Wardlaw 2003) . Late recognition of pregnancy is a strong predictor of delayed ANC attendance (Myer and Harrison 2003; Stanton et al. 2006; Gross et al. 2012; Andersen et al. 2013] .
Integrated service delivery
Integrating maternal, neonatal, child health, nutrition and family planning services improves coverage, quality and use of these services (Kennedy et al. 2011) . In addition, integrated services are more cost effective compared to single 'top-down' interventions. This is largely attributable to cost savings related to economies of scope (Tan-Torres Edejer et al. 2005; Kerber et al. 2007) . Furthermore, packaged services enable a more efficient use of women's time (Ringheim et al. 2011) .
Community-based provision of family planning services has been shown to be an effective approach to expanding access to quality services (Gallo et al. 2013) . It is widely recognized that CHWs can be instrumental in the identification of pregnant women in their communities and can provide a variety of services including family planning, birth planning, complication readiness, and referral for ANC and skilled delivery care (Antenatal Care 2005; Gallo et al. 2013) . At least 14 sub-Saharan African countries have existing CHW programs that deliver maternal health services and family planning commodities (including oral and injectable contraceptivesthe most popular forms of modern contraception in these countries) (Advancing Partners and Communities 2014).
Determining pregnancy status
The WHO recommends that family planning service providers rule out the possibility of pregnancy before providing hormonal contraceptives (World Health Organization 2004) . In many African countries, CHWs have been trained to use the simple six-question pregnancy checklist, a low-cost tool developed to rule out pregnancy before providing hormonal contraceptives. However, the checklist has a false positive rate ranging from 11 to 61%, which means that women may be denied hormonal contraceptives (Tepper et al. 2013) .
1 As a result, these women run the risk of becoming pregnant by only being able to access these contraceptives once they can prove they are not pregnant (such as when they are menstruating). Thus, the introduction of urine pregnancy tests kits can complement the use of the checklist to rule out pregnancy for those identified as 'possibly pregnant' by the checklist. A urine pregnancy test kit is a paper strip sealed in a package measuring approximately 20 by 60 centimeters. Urine pregnancy tests have typically been unaffordable in low resource settings, but the costs for these paper strip versions have fallen to as low as 10 cents per test (Management Sciences for Health 2014). The strip is dipped into a cup with urine. A color change on the strip within five minutes will indicate whether a pregnancy is detected. The product has a shelf life of two to three years. Because of the simplicity of use, the test can easily be administered by lay health workers at the community level to enhance family planning services and ANC referral. Community health workers can use these tests both to rule out pregnancy, enabling them to provide hormonal contraceptives, or to detect a pregnancy, allowing them to refer a woman for comprehensive prenatal services.
An evaluation of a pilot program that trained CHWs in Nepal in early pregnancy detection using urine pregnancy tests, counseling, and referral found that 100% of women testing positive for pregnancy were referred for appropriate reproductive health services (Andersen et al. 2013) . A recently published impact evaluation completed in Madagascar found that providing free urine pregnancy tests to CHWs increased the percentage of clients obtaining oral or injectable contraceptives by 26% compared to a control group, where CHWs did not have access to free urine pregnancy tests for use with their clients. The study concluded that community-based family planning programs in developing countries should consider including these tests as a low-cost addition to CHWs' services (Comfort et al. 2016) .
The provision of urine pregnancy testing has two potential outcomes. First, for women who are not pregnant, the test can more accurately rule out pregnancy and reduce denial of hormonal contraceptives as shown in Madagascar and Zambia (Stanback et al. 2013; Comfort et al. 2016) . Second, women who are determined to be pregnant by the urine test could be counseled and referred for antenatal care sooner than they would otherwise (Tepper et al. 2013) . Thus, the introduction of urine pregnancy tests could allow women who are not pregnant to obtain hormonal contraceptives when they otherwise might not be able to (reducing the probability of maternal and infant death by avoiding pregnancy); and, allow women who are pregnant to seek ANC services earlier and more frequently than they otherwise would (reducing neonatal mortality from earlier receipt of ANC).
Methods
We used a cost-effectiveness decision tree model to structure the analysis and guide calculations. The model is constructed based on the program scale-up experience in Madagascar. We compare the program/intervention (distribution of pregnancy test kits by CHWs) with the counterfactual of maintaining the status quo (exclusive use of the pregnancy checklist by CHWs to determine pregnancy status). We also completed sensitivity analyses to quantify uncertainty in the model; and, we conducted Monte Carlo simulations with 10 000 iterations to estimate the distribution and uncertainty limits for our cost per life saved calculations. We constructed the decision tree model and completed all analyses using Excel 2016 (Microsoft Corporation, Redmond, WA) and TreePlan (TreePlan Software, San Francisco, CA).
Model inputs are based primarily on published literature, and secondary analysis of each country's most recent Demographic and Health Survey (DHS) . Mortality data was extracted from the World Health Organization's Global Health Observatory data repository. Cost data are based on actual procurement costs as well as comparative, multi-country costing studies.
Probability estimates are based, to the greatest degree possible, on published estimates; in the case where there are multiple studies, an unweighted mean of the estimate was calculated and the lowest and highest point estimates were used in the sensitivity analysis. We used logistic regression analysis to calculate country-specific probabilities related to the completion of four or more ANC visits among women receiving early antenatal care.
The perspective, time-horizon, component parts of the measures of the costs and estimated effects of the interventions as well as associated variation are described below. Statistical analyses undertaken, probability calculations, and outcome measures are also described. This study follows the WHO guidance on cost-effectiveness analysis and aligns with the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (World Health Organization, 2003; Husereau et al. 2013 ).
Target population and subgroups
We designed a model to estimate the cost-effectiveness and mortality impact of providing free urine pregnancy tests to CHWs for distribution within a hypothetical population of 100 000 rural women of reproductive age in each of the three target countries: Madagascar, Ethiopia, and Malawi. Although the target population is considered rural women, infants and neonates are considered as a subgroup, as family planning reduces infant mortality through primary prevention; and, antenatal care has a direct impact on the reduction of neonatal mortality.
Country selection
Madagascar, Ethiopia and Malawi are of interest for this study as all three countries have large, existing CHW programs that provide a community-based service delivery platform to increase access to maternal and family planning services in remote and rural areas. There are certain distinctions between the three community-based programs. In Madagascar, the Community Health Volunteers are community members who receive health training to provide oral and injectable contraceptives. Madagascar was the first country in sub-Saharan Africa to allows CHWs to administer injectables at the community level (Family Health International 2008; Hoke et al. 2012) . In Ethiopia, the Health Extension Workers function more as auxiliary nurses who administer implants, as well as provide shortacting hormonal contraceptives and who provide maternal and child health services at the health post. In Malawi, the Health Surveillance Assistants only provide injectables, and work alongside community agents who provide oral contraceptives and condoms (Graham, March 3, 2016) . Overall, all three countries have the structure to add urine pregnancy tests to the service package provided by CHWs. Madagascar was selected as the base case to develop the model as it is presently scaling-up the intervention based on country evidence and initiative.
Likewise, all three countries have similar family planning profiles. Each country's modern contraceptive prevalence rate (CPR) has an annual mean increase of approximately 1.45% over the past 10-15 years. Oral and injectable contraceptives are overwhelmingly the methods of choice, particularly in rural areas: in Malawi, twothirds of users opt for short-acting hormonal methods; and, in Madagascar and Ethiopia, more than four out of every five women (85 and 83%, respectively) using a modern method family planning method choose oral or injectable contraceptives. These similarities are important as they demonstrate a degree of comparability among the three countries related to family planning method preferences and the need for community health workers to rule out pregnancy using the pregnancy checklist when they do not have access to urine pregnancy tests.
National trends for family planning use and antenatal care are shown in Figure 1 . The figure also includes current (2015) estimates where available and country commitments/targets for the year 2020. Rural areas lag behind urban areas, in terms of use of modern contraceptives, which is why availability of urine pregnancy tests in these areas has the potential for a large impact. Since our primary focus is on rural areas, we use data from rural areas whenever available for all calculations. However, because several point estimates (particularly mortality) are only available as national statistics, this study is considered to be conservatively biased as the situation in rural areas is presumed to be comparatively worse.
Study perspective
Given chronic budget constraints and multiple competing priorities related to developing country governments' financing for the health sector, we adopted the donor perspective as this is the most likely source of initial funding for the initiative. Donor funding currently supports the CHW program in Madagascar. In addition, the introduction of new technologies in low-resource countries is most commonly facilitated, initially, with strong donor support-as donors are often in a better position to mobilize technical assistance and program financial resources. Finally, the potential economies of scale related to commodity procurement led us to assume that the most likely catalytic stakeholder for the scale-up of the intervention would be an international donor. Our analysis does not focus on the costs incurred by clients given the donor perspective. In some instances, clients' costs will fall with the introduction of pregnancy test because they will not need to visit CHWs multiple times to rule out pregnancy. However, clients may incur higher costs for additional ANC visits given earlier detection of pregnancy.
Choice of health outcomes
The primary health outcomes of interest are neonatal, infant and maternal deaths. Mortality estimates are aggregated and expressed as deaths averted or lives saved. In addition, Years of Life Lost (YLL) averted are also calculated and aggregated by country. A Disability Adjusted Life Years (DALYs) is the sum of years of potential life lost due to premature mortality and the years of life lost due to disability. A Year of Life Lost (YLL) is the number of deaths multiplied by a standard life expectancy at the age of death. As our outcome of interest is mortality and we do not consider disability, our DALYs are equivalent to YLLs because there is no adjustment for years lived with disability.
Estimating intervention costs
We grouped intervention costs (i.e. addition of urine pregnancy test to an existing CHW program platform) into three categories: (1) commodity procurement, (2) in-country commodity supply chain, and (3) support costs. The latter includes supplies, training, incentives, management and overhead. All costs are presented in 2016 US dollars. Base costs were adjusted to 2016 US dollars using a cumulative inflation rate of 3.3%. Table 1 shows annual unit costs used in the model by category for the three countries.
Commodity procurement
All base costs are actual costs in 2016 US Dollars provided by USAID/Madagascar (Rakotomanga 2016) . As these costs are centrally negotiated, they do not vary by country. Most countries in sub-Saharan Africa are in the process of transitioning from a standard injectable with syringe to Sayana Press which uses an all-in-one injectable that combines the contraceptive drug and needle in the Uniject TM injection system. To incorporate the cost difference of the two products into the model, we calculated the mean cost. Both products provide three months of protection from pregnancy, therefore the total cost was multiplied by four to determine the annual cost per user of injectables. One blister-pack of oral contraceptives provides one month of protection; therefore, the associated costs were multiplied by 12 to calculate the annual cost per user. International commodity shipping costs assume that 20% of the product is shipped via air at a cost equal to 23% of the product cost; and, 80% of the product is shipped via sea at a cost equal to 7% of the cost (Rakotomanga 2016) . Freight charges are 5.5% of commodity cost (Rakotomanga 2016) . This resulted in an international shipping cost of $0.18 per injectable. The index/composite cost per injectable contraceptive client for 1-year is $5.32. Method type weights were applied to estimate the overall average cost per user of hormonal contraceptives (either oral or injectable) for one full year of protection. The weight was calculated by averaging the proportional (rural) usage of each method for each country. This proportion was applied to calculate an average cost per short-acting, hormonal user as it is assumed that new users will choose these methods in these same proportions as current users.
The procurement and shipping costs of pregnancy test kits is $0.25 per unit. The model assumes one test per year. The model does not include costs related to initial pipeline and buffer stocks; likewise, product wastage and losses have not been included in this analysis because we were unable to identify source data for these estimates. Furthermore, the model includes the full cost of pregnancy test kits and does not assume any monetary cost to the end user.
In-country commodity supply chain For the in-country commodity supply chain, calculations are based on the "Estimating the Global In-Country Supply Chain Costs of Meeting the MDGs by 2015" report (Sarley et al., 2009) . The report uses a country classification system and a comprehensive information review to estimate in-country distribution and logistics costs for different health commodity groups.
The total contraceptive cost per woman by country is $6.05 (Madagascar), $6.76 (Ethiopia), and $6.36 (Malawi). This is the average total cost per user per year $4.94 (Madagascar), $5.22 (Ethiopia), and $5.19 (Malawi) plus in-country commodity supply chain costs $1.11 (Madagascar), $1.57 (Ethiopia), and $1.17 (Malawi). We used uncertainty intervals provided in the Estimating Supply Chain Costs report to vary the in-country supply chain costs for each county in the sensitivity analysis (by 6 2.5% for Madagascar and Malawi; and 6 5% for Ethiopia) (Sarley et al. 2009 ).
Support costs
Estimates of support costs were derived from the 'One Million Community Health Workers, Technical Task Force Report' (The Earth Institute 2012). This report provides annual costs for CHW supplies, training, incentives, management and overhead by country. We estimate that the CHW level of effort (LOE) associated with the administration of pregnancy tests to be 5%. This estimate is based on an operations research study conducted by Management Sciences for Health (MSH) in Madagascar during the scale-up efforts for providing pregnancy tests by CHWs. This study found that CHWs provide three tests, on average, per month (Yanulis 2016) .
In addition, MSH estimates the maximum total time dedicated to manage stock, counsel, administer, record, and disclose the result of one pregnancy test is 45 min. We used the maximum to avoid underestimating this input. Thus, we estimate that a CHW spends 135 min per month on pregnancy testing (45 min per test multiplied by 3 tests) (Ralidera 2016 ). According to Gallo et al. (2013) , CHWs dedicate an average of 11.5 h per week to their work which equals 2,760 min per month (11.5 h multiplied by 60 min multiplied by 4 weeks). Therefore, the time dedicated to pregnancy testing is estimated to be 5% of the total LOE. We also varied the support cost estimate by 6 15% in the sensitivity analyses. In order to establish a cost per unit, we divided the proportional cost by an average of 36 tests administered by one CHW over one year (or three tests on average per month).
Choice of model
A decision tree model was developed to organize and consolidate inputs, risk proportions/probabilities, pathways, and associated mortality outcomes. This allowed for a comparison of costs and associated mortality outcomes of the intervention scenario with the counterfactual, meaning the status quo where the pregnancy test is not offered and the CHWs rely solely on the checklist to determine pregnancy status.
The tree is divided into two primary branches: the top branch is the no-test or status quo scenario; the bottom branch is the pregnancy test or intervention scenario. The sub-branches, representing different outcomes, are the same for both no-test and test scenarios. The risk proportions or probabilities associated with each possible outcome are used to calculate the number of women from our hypothetical cohort that follow a specific pathway. Additive unit costs, associated with the provision of pregnancy tests, are also shown. Figure 2 is the decision tree presented with Madagascar specific inputs.
Assumptions and study parameters
The decision tree model tests the costs and mortality effects of a hypothetical cohort of 100 000 women of reproductive age who seek CHW services related to family planning and maternal health services. The decision tree model assumes an existing network of CHWs, in remote and rural communities, who provide maternal and reproductive health services, specifically family planning counseling and commodities as well as antenatal referrals. Results are expressed as an Incremental Cost Effectiveness Ratio (ICER), which is the difference in benefit relative to costs of the intervention compared to the counterfactual. All inputs, cost estimates, and outcomes for the analysis are based on a 1-year period.
Because all three countries have existing cadres of CHWs who offer family planning and maternal health services, no additive costs are calculated in the no-test branch. However, all commodity procurement and supply chain costs for oral and injectable contraceptives were included in both scenarios in order to control for these costs in relation to the expected increase or premium in contraceptive uptake among clients in the program/intervention branch-those receiving a urine pregnancy test. This was done to capture the marginal increase in costs for oral and injectable contraception resulting from the use of the pregnancy tests. Model parameters applied to the three countries are shown in Table 2 .
Assumptions and related calculations are explained using data specific to Madagascar. Country-specific variables and values are shown in Table 3 . The proportion of women who are pregnant from the population of women seeking CHW services is assumed to be equal to the pregnancy risk rate. We calculated this rate by adjusting the birth rate to represent the average annual number of births during a year per 1000 women of reproductive age (WRA) who are not Figure 2 . Decision tree using a modern family planning method. We recognize that this method underestimates the proportion of women becoming pregnant as the birth rate does not include women who were pregnant, but did not carry to term. Therefore, our estimates are conservative. The formula is shown below.
where WRA is women of reproductive age and MCPRr is modern contraceptive prevalence rate (rural) For Madagascar, we estimated that, among women not using a modern family planning method, one in five women (18.8%) will get pregnant over a one-year period. This proportion was applied to both the non-test and test branches of the decision tree.
We calculated the optimized uptake of short-acting, hormonal contraception which is the proportion of all women of reproductive age who have an unmet need, are not pregnant, and would choose either oral or injectable contraceptives. First, we adjusted the unmet need in rural areas to remove pregnant women from the denominator. Second, we performed another adjustment to account for the method specific discontinuation rates (by country). Finally, we multiplied the adjusted unmet need in rural areas by the proportion of women who choose either an oral or injectable contraceptive. This rate is applied in the intervention branch among women who are not pregnant to predict oral/injectable contraceptive uptake. Estimates by country are shown in Table 3 .
The test branch assumes that adoption of a short-acting, hormonal method is 26% higher than the no-test branch. This value is extrapolated from the randomized controlled study undertaken by Comfort et al. (2016) on the introduction of urine pregnancy tests in Madagascar (Comfort et al. 2016) . To calculate the short-acting family planning method adoption rate for the no-test branch, we reduced uptake to (1/1.26) or 79% of the total possible uptake. This difference may reflect both the mis-classification of non-pregnant women as being 'potentially pregnant' per the checklist as well as adoption of contraceptives by women who have a negative pregnancy test and subsequently request hormonal contraceptives. These two factors are hypothesized to contribute to the uptake of hormonal contraceptive methods in the intervention group.
The risk of pregnancy among women adopting a family planning method was calculated by applying method specific effectiveness rates to rural method use rates for each country. For example, in Madagascar, among short-acting hormonal contraceptive users, 24% use pills and 76% use injectables. Oral contraceptives are 92% effective to prevent pregnancy with "common" versus perfect use; injectable contraceptives are 97% effective (World Health Organization 2016). Thus, we calculated the pregnancy risk as follows: Pregnancy risk rate among short-acting hormonal contraceptive users ¼ 1-((24%*92%) þ (76%*97%)) ¼ 4.2%.
This rate is applied to women who adopt oral or injectable contraceptives to calculate number of women and infants exposed to mortality risk because they become pregnant due to method failure.
The model includes two possible initial outcomes for pregnant women: they either seek early ANC services or do not. For pregnant women in the no-test branch, we used the actual early ANC attendance rates. For Madagascar, that rate is 27.4% (National Statistics Institute, 2008) . For the test branch, we estimated the referral compliance rate by multiplying the average of five estimates from the most relevant peer reviewed studies on the topic (yielding 30.4% with a range of 12 to 46%) by the actual proportion of women referred by a CHW following a positive pregnancy test as reported by MSH (92.5%) (Jahn and Brouwere 2001; Yanulis 2016) . We varied the referral rate from 85 to 100% in the sensitivity analysis. We assumed that the proportion represented a premium or net increase over the no-test base level from each country's most recent Demographic and Health Survey. Thus, for Madagascar, the optimized early ANC attendance (applied to the test branch) is estimated to be 55.5%.
The difference in early ANC attendance rates assumes that women accessing a pregnancy test will know their pregnancy status earlier than they otherwise would and therefore would be referred earlier to ANC services.
Women who are not pregnant and who choose not to adopt a method are at higher risk of pregnancy. The pregnancy risk rate was used to estimate the proportion of women of reproductive age not using a modern family planning method who are expected to become pregnant over the year. Because there is no plausible direct effect of pregnancy testing among these women, we do not model the effects of ANC attendance nor its main effect on neonatal mortality. However, we capture mortality risk by applying country-specific mortality rates to these pregnancies in both the test and no-test branches.
We used logistic regression analysis to calculate country-specific probabilities related to the completion of four or more antenatal care visits among women receiving early antenatal care (defined as within the first four months of pregnancy). This analysis controlled for: woman's education, husband's education, marital status, availability, cost, household income, woman's employment, media exposure, urban/rural residence, and distance to the nearest facility as a factor limiting facility-based deliveries (Simkhada et al. 2008) . Calculated probabilities were held constant for both the no-test and test scenarios.
In relation to health outcomes, we reduced neonatal mortality by 15% among births for those completing at least four ANC visits (Darmstadt et al. 2005 ). As noted above, women using a family planning method were considered to be at risk following the weighted method specific effectiveness rates. We applied countryspecific maternal and infant mortality rates for each pregnancy/ birth.
Finally, it is important to note that the additional cost of oral and injectable contraceptives resulting from increased uptake in the program/intervention branch (e.g. due to pregnancy test kits) is included as a program cost as it is an expected result of the intervention. It is a necessary cost that otherwise would not have been incurred and is a required cost in order for those women to no longer be at risk of pregnancy and therefore maternal mortality. Country specific study parameters included in the model are shown in Table 3 . Table 4 shows the estimated lives saved, total cost, cost per life saved, YLL averted, and the cost per YLL averted by country.
Results
Among
For Madagascar, the lives saved estimate is driven by lower birth rates and higher ANC attendance compared to Ethiopia and Malawi. In addition, Ethiopia and Malawi have higher (adjusted) unmet need for family planning. Malawi's higher death rates yield larger mortality reductions which results in lower cost per life saved and YLL averted. The primary cost driver overall is the increased use of oral and injectable contraceptives. Ethiopia's more expensive CHW system and in-county transportation, render the total additive cost to be 1.7 times higher than Madagascar and Malawi. Likewise, the cost per YLL or DALY averted in Ethiopia is over 1.3 times higher compared to Madagascar, and nearly 2.2 times the cost per life saved in Malawi.
Characterizing uncertainty
To quantify uncertainty, we completed country-specific sensitivity analyses. We tested the effect of upper and lower uncertainty limits on nine critical input variables. The single factor analysis revealed that two variables contribute most significantly to uncertainty in the results: (1) neonatal mortality rates; and (2) the increase in uptake of short-acting FP methods. Importantly, but to a lesser degree, infant mortality rates and the ANC referral compliance rate also contribute to uncertainty in the model. These findings were consistent across the three countries. The tornado diagrams are shown in Figure 3 . Higher mortality rates are associated with lower cost per death averted. Increased uptake in short-acting hormonal FP methods following pregnancy testing would also reduce the cost per death averted. Likewise, as ANC referral compliance increases, the intervention may become more cost effective. To a lesser degree, the Finally, we completed country-specific Monte Carlo simulations with 10 000 iterations to estimate the distribution and uncertainty limits for each cost per life averted estimate. The uncertainty limits are included in the results section above. Figure 4 shows the distribution graphs for each country.
Discussion
Typically, women have not had access to urine pregnancy tests at affordable prices. There is recent evidence that pregnancy test kits are becoming commercially available through local pharmacies in some urban and peri-urban areas, based on a study conducted in Kenya, Malawi and Mali. However, the results also show that the retail price of pregnancy tests is, on average, marked up between 4 and 21 times the procurement price of $0.10 (Rademacher 2016). In addition, access, particularly in the rural areas where CHWs provide services, is assumed to be highly limited even though the costs of these paper strip tests has significantly fallen.
We would also like to note that the effect of reduced neonatal mortality related to four or more ANC visits assumes that the entire package of ANC services are available, women receive them, and the services meet minimum quality standards.
In relation to referral/care-seeking for ANC, as presented in the background section of this study, there is little debate relating to the importance and benefits of early ANC care-seeking. However, more evidence is needed to quantitatively evaluate the causal pathway for increased ANC referral (resulting from a positive pregnancy test) leading to increased early ANC attendance. Adding pregnancy test kits to the maternal and reproductive services package at the community level could accelerate uptake of family planning and antenatal care services resulting in a decrease in maternal, neonatal, and infant mortality and DALYs. We calculate the cost per DALY averted to be $36.28 for Madagascar, $47.95 for Ethiopia and $21.92 for Malawi.
As a guideline for low-resource countries, WHO considers an intervention to be cost-effective when the cost per DALY averted is less than three times the Gross Domestic Product (GDP) per capita; interventions that cost less than GDP per capita are classified as highly cost-effective.
A recently published comparative review of 31 reproductive, maternal, newborn, and child health interventions found only nine interventions to have a cost per DALY under $100. Those interventions are: (1) education programs on nutrition/water, sanitation and hygiene; (2) clean delivery kit and training traditional birth attendants; (3) management of obstructed labour; (4) community management of severe malnutrition; (5) micronutrient interventions (biofortification, fortification, supplementation); (6) maternal and neonatal care at home; (7) zinc added to oral rehydration therapy and (8) home management of fever with antimalarials versus referral. Treatment of severe malaria with artesunate compared to quinine in Africa was the only intervention to yield a cost per DALY under $10 (2012 USD). All other interventions were found to cost in excess of $100 per DALY (Horton et al. 2016) .
In addition antenatal syphilis screening using point-of-care testing in Sub-Saharan African countries is assessed to cost an average US$12.02 (2016 USD) per DALY averted (Kuznik et al. 2013) . And, a study conducted in Bangladesh estimates that if chlorhexidine (for neonatal infection control) is added to an existing community-based essential newborn care program, the mean incremental cost per DALY averted is less than US $10 (Chlorhexidine Working Group 2016). Likewise, a study focusing on community-based distribution of misoprostol for post-partum hemorrhage in rural India estimated the cost per DALY saved to be $7.38 for treatment and $209.08 for prevention (Sutherland et al. 2010) .
As our analysis is based on a model, several assumptions were required such as using Madagascar as our base example.
We also note that certain costs were not included in our model, such as wastage and losses, or costs incurred by the user, because of data availability and the donor perspective used for this study. In countries where CHWs are not already providing contraceptives, costs related to demand creation for example may be important to consider. However, as noted by Darmstadt (2008) , "modelling costs and impact of intervention packages scaled up. . . can assist programme planning and help policy makers and donors identify stepwise targets for investments in newborn health" (Darmstadt et al. 2008) .
Based on WHO criteria and a comparison with other maternal, newborn and child health interventions, we conclude that, at a cost per DALY averted of $36.28 (Madagascar), $47.95 (Ethiopia) and $20.92 (Malawi), the addition of urine pregnancy tests to an existing CHW maternal and reproductive services package is highly costeffective for each of the three countries.
The addition of low cost, easy-to-use urine pregnancy tests to the package of services and products provided by CHWs may offer a unique and cost-effective opportunity to increase access to and utilization of proven, live-saving health services, both for women who test positive or those who test negative for pregnancy. These findings show that decision makers and program planners should consider the addition of pregnancy tests to the community service package.
